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Recently several randomized trials have demonstrated the excellent role of the implantable
cardioverter-deﬁbrillator (ICD) in improving the mortality rate in patients with a high risk
of sudden cardiac death regardless of its purpose or the underlying heart disease. However,
because such large clinical trials have only been carried out in Western countries, those results
may not be fully applicable to Japanese or other Asian patient populations.
According to a Japanese study, the total mortality in the patients was approximately 20%
during 5 years of follow up, which was comparable to, or slightly better than that in the
MADIT-II patients with ICDs. In such a patient population with an excellent prognosis, the
MADIT-II criteria can not easily be applied. Therefore, we should strengthen the criteria, i.e.
from an EF  35% to 25% or adopt the usage of additional examinations (e.g. signal
averaging ECG, micro-volt T wave alternance or EPS).
(J Arrhythmia 2007; 23: 264–268)
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Introduction
Recently several randomized trials have demon-
strated the excellent role of the ICD in improving the
mortality rate in patients with a high risk of sudden
cardiac death regardless of its purpose (primary or
secondary prevention) or the underlying heart dis-
ease (ischemic or non-ischemic). However, because
such large clinical trials have only been carried out in
Western countries, those results may not be fully
applicable to Japanese or other Asian patient pop-
ulations. In 2006, ICDs with the capability of cardiac
resynchronization (CRT-D) were approved in Japan.
The newest devices are expected to provide further
improvement in the mortality and/or quality of life
(QOL) in patients with heart failure. However, their
high cost may impose a burden on our limited resour-
ces if they are used without careful consideration.
The purpose of this article was to review the
various large randomized trials that used ICDs,
and to discuss a more eﬀective usage of ICDs for
primary prevention in Japanese or other Asian
patients with a prior myocardial infarction (MI)
based on the proper interpretation of the evidence
gained from the Western countries.
1. MADIT1)
MADIT was the ﬁrst clinical trial which demon-
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strated the eﬃcacy of the ICD for primary preven-
tion in patients with ischemic heart disease. The
study included very high risk patients for sudden
cardiac death (non-sustained VT, prior Q wave MI,
EF  35%, or inducible sustained VT not suppressed
by procainamide at the electrophysiologic study), and
compared the total mortality between the patients
treated with only antiarryhymic drugs (mainly amio-
darone) and those with ICDs. The study showed that
the ICD decreased the total mortality by 54%.
2. MUSTT2)
MUSTT tested the hypothesis that an electro-
physiologic study (EPS)-guided antiarrhythmic ther-
apy (antiarrhythmic drugs and/or ICD) would reduce
the risk of arrhythmic death in patients with MI and
non-sustained VT. The inclusion criteria were an
EF 5 40%, >1 week post-MI and inducible sus-
tained VT by EPS. However, ultimately the study
reached the main conclusion that ICD therapy alone
improved the mortality rather than proving the
original hypothesis of the study which was to
demonstrate the superiority of the EPS-guided
antiarrhythmic therapy. The ICD reduced the total
mortality by 50% compared to the non-EPS-guided
group.
3. MADIT-II3)
Following the very encouraging results from
MADIT, MADIT-II was conducted to evaluate the
eﬃcacy of the ICD in lower-risk patients with MI.
A total of 1,232 MI patients with an EF 5 30% were
randomly assigned at a ration of 3:2 to ICD and
conventional therapy groups. The documentation
of non-sustained VT and inducibility of sustained
VT/VF were not required. The study demonstrated
a 31% reduction in the total mortality with ICD
therapy.
4. SCDHeFT4)
SCDHeFT was designed to evaluate the eﬃcacy
of ICD therapy and amiodarone in patients with
heart failure due to ischemic or non-ischemic causes.
A total of 2,521 patients with a New York Heart
Association (NYHA) class II or III and an EF  35%
were evenly assigned to placebo, amiodarone or ICD
groups. All patients received conventional therapy
for their heart failure. As compared to the placebo
group, the ICD therapy group was associated with a
23% decreased risk of sudden death in the overall
patients and 21% in the patients with ischemic heart
disease. Amiodarone did not improve the patient
outcome.
5. Comparison of the Four Randomized Studies
Figure 1 shows the improvement in the total
mortality achieved by ICD therapy in each study.
The MADIT and MUSTT studies which enrolled
more risky patients for sudden cardiac death (doc-
umentation of non-sustained VT and induction of
sustained VT/VF by EPS) demonstrated more than a
50% reduction in the total mortality. On the other
hand, MADIT-II and SCDHeFT, which expanded
the inclusion criteria to patients with a lower risk,
reduced the mortality by 20–30%. That diﬀerence
might be due to the level of the risk for arrhythmic
death in the enrolled patients. Therefore, it could
be interpreted that the recognition of non-sustained
VT and induction of VT/VF by EPS are eﬀective
methods for risk stratiﬁcation and may result in
the eﬀective usage of ICDs in patients with MI.
However, in 2005, the AHA/JACC task force
accepted MADIT-II criteria as a class I indication
for an ICD implantation.5) That decision may have
been based on the high incidence of sudden cardiac
death of MI patients in North American people and
on the limitations (high false negative values) of the
EPS. According to a MUSTT sub-study, EPS was
‘‘statistically’’ eﬀective in predicting the occurrence
of sustained VT/VF episodes in patients with MI,
but false negative values of the EPS (20% during
5 years of follow up) were too high to ignore
(Figure 2).6) For example, when we are faced with a
certain fatal but almost curative disease being treated
properly, which is very representative of ICD
therapy in VT/VF patients, we should expend
maximum eﬀort to avoid any false negative results
when predicting the patient outcome. If we fail to
select an appropriate therapy for such patients, the
result could be very serious.
Expanding the indications of ICDs in patient
populations with a very high risk for sudden death
(such as in North American MI patients) is thought
to be reasonable.
6. Prognosis of MI Patients in Japan
Many Japanese medical doctors who are coronary
interventional specialists may feel that the prognosis
of Japanese MI patients is much better than that in
MADIT-II. The total mortality in the control group
of the MADIT-II trial reached more than 30% during
5 years of follow up. Furthermore, approximately
half of the patients died suddenly. Tanno et al.
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(Showa University) retrospectively investigated the
prognosis of Japanese patients who met the criteria
of MADIT-II.7) Figure 3 shows the Kaplan-Meier
curves plotted with the data from their series and
from MADIT-II. Surprisingly, the total mortality in
the patients from Showa University (approximately
20% during 5 years of follow up) was comparable
to, or slightly better than that in the MADIT-II
patients with ICDs. Furthermore, they described that
sudden cardiac death was observed in only 2 out of
9 deaths (22%). A large prospective cohort study in
the Osaka area (OACIS) also demonstrated similar
results.8) In such a patient population with an
excellent prognosis, the MADIT-II criteria can not
easily be applied.
7. Relationship between the Incidence of Events
and the Diagnostic Criteria
A perfect clinical examination which completely
predicts the patient outcome never occurs. All
examinations always produce both false positive
and false negative results. Figure 4A demonstrates a
certain examination with a 1:3 ratio of the proba-
bility of false negative and false positive results by
assuming an incidence of 50%. In that case, the
degree of false negative results, indicated by the
closed area, were thought to be acceptable. Assum-
ing there was a 10% incidence (Figure 4B), the false
negative area would become very small and could
be ignored. On the contrary, the false positive area
(the dotted area) greatly expands, which may lead to
an inappropriate indication for therapy in many
patients. This could be applied to the low incidence
of sudden cardiac death in Japanese MI patients. A
criteria which had been adequate for a population
with a high incidence of events (e.g. an EF < 35%
and sudden cardiac death in North American MI
patients) could not directly be used in those with
better outcomes. Therefore, we should strengthen the
criteria, i.e. shift the cut-oﬀ line to the right (e.g.
from an EF  35% to 25%) or adopt additional
examinations (e.g. the signal averaging ECG, micro-
volt T wave alternance or an EPS).6,9)
Unadjusted P=0.005
Adjusted P<0.001
Inducible tachyarrhythmias,
no antiarrhythmic therapy
Registry
(No inducible
                     tachyarrhythmias)
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pr
op
or
tio
n 
of
 P
at
ie
nt
s
0 1 2 3 4 5
Years after Enrollment
No. AT RISK
Inducible tachyarrhythmias,
   no antiarrhythmic therapy
Registry
353 
1397
290 
1212
242 
1074
178 
787
118 
530
67 
308
Figure 2 The role of the electro-
physiologic study (EPS) in post-MI
patients.
EPS was statistically eﬀective in pre-
dicting the occurrence of sustained VT/
VF episodes in patients with an MI, but
false negative values from the EPS (a
VT/VF incidence in the non-inducible
group, the registry, of 20% during 5
years of follow up) were still too high
to ignore.
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Figure 1 Improvement in total mortality in the ICD group
as compared with the control (non-ICD) group in each
randomized study.
The MADIT and MUSTT studies which enrolled more risky
patients for sudden cardiac death (documentation of non-sustained
VT and induction of sustained VT/VF by EPS) demonstrated
more than a 50% reduction in the total mortality. On the other
hand, MADIT-II and SCDHeFT, which expanded the inclusion
criteria to patients with a lower risk, reduced the mortality by 20–
30%.
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Figure 3 The total mortality in Japanese
patients who met the MADIT-II criteria.
Tanno et al. (Showa University) retrospectively
investigated the prognosis in Japanese patients
who met the criteria for MADIT-II. This Figure
shows the Kaplan-Meier curves plotted with the
data from their series (our series are in the
ﬁgure) and from MADIT-II. Surprisingly, the
total mortality in the patients from Showa
University (approximately 20% during 5 years
of follow up) was comparable to, or slightly
better than, that in the MADIT-II patients with
ICDs. Furthermore, they described that sudden
cardiac death was observed in only 2 out of 9
deaths (22%).
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